{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04126200",
            "orgStudyIdInfo": {
                "id": "208887"
            },
            "organization": {
                "fullName": "GlaxoSmithKline",
                "class": "INDUSTRY"
            },
            "briefTitle": "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)",
            "officialTitle": "A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5",
            "acronym": "DREAMM5",
            "therapeuticArea": [
                "Other"
            ],
            "study": "platform-study-of-belantamab-mafodotin-as-monotherapy-and-in-combination-with-anti-cancer-treatments-in-participants-with-relapsed-refractory-multiple-myeloma-rrmm"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": true,
                "nctId": "NCT03763370",
                "statusForNctId": "AVAILABLE"
            },
            "startDateStruct": {
                "date": "2019-10-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-02-24",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-02-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-10-11",
            "studyFirstSubmitQcDate": "2019-10-11",
            "studyFirstPostDateStruct": {
                "date": "2019-10-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "GlaxoSmithKline",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously."
        },
        "conditionsModule": {
            "conditions": [
                "Multiple Myeloma"
            ],
            "keywords": [
                "Belantamab mafodotin",
                "GSK2857916",
                "GSK3174998",
                "Feladilimab",
                "Nirogacestat",
                "Dostarlimab",
                "Isatuximab",
                "Lenalidomide",
                "Dexamethasone",
                "Pomalidomide",
                "Platform study",
                "Relapsed/Refractory Multiple Myeloma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "There will be a dose exploration (DE) phase which will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with other anti-cancer treatments. A recommended Phase 2 dose (RP2D) for each combination treatment will be identified based on the safety and preliminary efficacy in DE. This will be followed by a cohort expansion (CE) phase which will evaluate the clinical activity of the combination treatment in comparison to belantamab mafodotin monotherapy in additional participants.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 464,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: GSK3174998"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Feladilimab"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Nirogacestat"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Dostarlimab"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Isatuximab"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Nirogacestat",
                        "Drug: Lenalidomide",
                        "Drug: Dexamethasone"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Nirogacestat",
                        "Drug: Dexamethasone",
                        "Drug: Pomalidomide"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 8)",
                    "type": "EXPERIMENTAL",
                    "description": "This cohort will enroll Northeast Asian participants.",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Nirogacestat",
                        "Drug: Lenalidomide",
                        "Drug: Dexamethasone"
                    ]
                },
                {
                    "label": "Belantamab mafodotin monotherapy cohort expansion",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: GSK3174998"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Feladilimab"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ nirogacestat cohort expansion (Sub-study 3)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Nirogacestat"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ dostarlimab cohort expansion (Sub-study 4)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Dostarlimab"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ isatuximab cohort expansion (Sub-study 5)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Isatuximab"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Nirogacestat",
                        "Drug: Lenalidomide",
                        "Drug: Dexamethasone"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Nirogacestat",
                        "Drug: Dexamethasone",
                        "Drug: Pomalidomide"
                    ]
                },
                {
                    "label": "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 8)",
                    "type": "EXPERIMENTAL",
                    "description": "This cohort will enroll Northeast Asian participants.",
                    "interventionNames": [
                        "Drug: Belantamab mafodotin",
                        "Drug: Nirogacestat",
                        "Drug: Lenalidomide",
                        "Drug: Dexamethasone"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Belantamab mafodotin",
                    "description": "Belantamab mafodotin will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin monotherapy cohort expansion",
                        "Belantamab mafodotin+ dostarlimab cohort expansion (Sub-study 4)",
                        "Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)",
                        "Belantamab mafodotin+ isatuximab cohort expansion (Sub-study 5)",
                        "Belantamab mafodotin+ nirogacestat cohort expansion (Sub-study 3)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 8)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 8)",
                        "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)",
                        "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)",
                        "Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)",
                        "Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)",
                        "Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)",
                        "Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)",
                        "Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)",
                        "Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "GSK3174998",
                    "description": "GSK3174998 will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)",
                        "Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Feladilimab",
                    "description": "feladilimab will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)",
                        "Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nirogacestat",
                    "description": "Nirogacestat will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin+ nirogacestat cohort expansion (Sub-study 3)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 8)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 8)",
                        "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)",
                        "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)",
                        "Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Dostarlimab",
                    "description": "Dostarlimab will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin+ dostarlimab cohort expansion (Sub-study 4)",
                        "Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Isatuximab",
                    "description": "Isatuximab will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin+ isatuximab cohort expansion (Sub-study 5)",
                        "Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Lenalidomide",
                    "description": "Lenalidomide will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 8)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 8)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Dexamethasone",
                    "description": "Dexamethasone will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 8)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)",
                        "Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 8)",
                        "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)",
                        "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pomalidomide",
                    "description": "Pomalidomide will be administered.",
                    "armGroupLabels": [
                        "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)",
                        "Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "DE Phase: Number of participants achieving dose limiting toxicities (DLT)",
                    "description": "An event is considered to be a DLT if the event occurs within the first 28 days of treatment and meets protocol defined DLT criteria.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "DE Phase: Number of participants with adverse events (AEs) and serious adverse events (SAEs)",
                    "description": "AEs and SAEs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "DE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters",
                    "description": "Blood and urine samples will be collected to evaluate hematology, clinical chemistry and urinalysis lab parameters.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants achieving Overall Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants with a Partial response (PR) or better, according to the International Myeloma Working Group (IMWG) Response Criteria.",
                    "timeFrame": "Up to 36 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "DE Phase: Number of participants achieving ORR",
                    "description": "ORR is defined as the percentage of participants with PR or better, according to the IMWG Response Criteria.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants achieving Clinical Benefit Rate (CBR)",
                    "description": "CBR is defined as the percentage of participants with a minimal response (MR) or better, according to IMWG response criteria.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants achieving Partial Response (PR)",
                    "description": "Number of participants with PR according to IMWG criteria will be analyzed.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants achieving PR",
                    "description": "Number of participants with PR according to IMWG criteria will be analyzed.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants achieving Very Good Partial Response (VGPR)",
                    "description": "Number of participants with VGPR according to IMWG criteria will be analyzed.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants achieving VGPR",
                    "description": "Number of participants with VGPR according to IMWG criteria will be analyzed.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants achieving Complete Response (CR)",
                    "description": "Participants with CR according to IMWG criteria will be analyzed.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants achieving CR",
                    "description": "Participants with CR according to IMWG criteria will be analyzed.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants achieving stringent Complete Response (sCR)",
                    "description": "Participants with sCR according to IMWG criteria will be analyzed.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants achieving sCR",
                    "description": "Participants with sCR according to IMWG criteria will be analyzed.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments",
                    "description": "Blood samples will be collected for concentrations of belantamab mafodotin.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments",
                    "description": "Blood samples will be collected for concentrations of belantamab mafodotin.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: GSK3174998 concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of GSK3174998.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: GSK3174998 concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of GSK3174998.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Feladilimab concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of feladilimab.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Feladilimab concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of feladilimab.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Nirogacestat concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of nirogacestat.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Nirogacestat concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of nirogacestat.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Dostarlimab concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of dostarlimab.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Dostarlimab concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of dostarlimab.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of isatuximab.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin",
                    "description": "Blood samples will be collected for concentrations of isatuximab.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Concentration of anti-drug antibodies (ADAs) against belantamab mafodotin when administered in combination with anti-cancer treatments",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Concentration of ADAs against belantamab mafodotin when administered in combination with anti-cancer treatments",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Concentration of ADAs against GSK3174998 when administered in combination with belantamab mafodotin",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Concentration of ADAs against GSK3174998 when administered in combination with belantamab mafodotin",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Concentration of ADAs against feladilimab when administered in combination with belantamab mafodotin",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Concentration of ADAs against feladilimab when administered in combination with belantamab mafodotin",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Concentration of ADAs against dostarlimab when administered in combination with belantamab mafodotin",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Concentration of ADAs against dostarlimab when administered in combination with belantamab mafodotin",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Concentration of ADAs against isatuximab when administered in combination with belantamab mafodotin",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Concentration of ADAs against isatuximab when administered in combination with belantamab mafodotin",
                    "description": "Blood samples for concentrations for ADAs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants with adverse events of special interest (AESI) for belantamab mafodotin",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants with AESI for belantamab mafodotin",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants with AESI for GSK3174998",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants with AESI for GSK3174998",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants with AESI for Feladilimab",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants with AESI for Feladilimab",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants with AESI for Nirogacestat",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants with AESI for Nirogacestat",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants with AESI for Dostarlimab",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants with AESI for Dostarlimab",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants with AESI for Isatuximab",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants with AESI for Isatuximab",
                    "description": "AESIs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "DE Phase: Number of participants with abnormal ocular findings on ophthalmic examination",
                    "description": "Ophthalmic examination will assess abnormal findings.",
                    "timeFrame": "Up to 12 months"
                },
                {
                    "measure": "CE Phase: Number of participants with abnormal ocular findings on ophthalmic examination",
                    "description": "Ophthalmic examination will assess abnormal findings.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "CE Phase: Number of participants achieving Progression-free survival (PFS)",
                    "description": "PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "CE Phase: Duration of response (DoR)",
                    "description": "DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "CE Phase: Time to response (TTR)",
                    "description": "TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "CE Phase: Number of participants achieving Overall survival (OS)",
                    "description": "OS is defined as the time from randomization until death due to any cause.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "CE Phase: Number of participants with AEs and SAEs",
                    "description": "AEs and SAEs will be collected.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "CE Phase: Number of participants with AEs leading to discontinuation",
                    "description": "Number of participants with AEs leading to discontinuation will be evaluated.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "CE Phase: Number of participants with dose reduction or delay",
                    "description": "Number of participants with dose reduction or delay will be evaluated.",
                    "timeFrame": "Up to 36 months"
                },
                {
                    "measure": "CE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters",
                    "description": "Blood and urine samples will be collected to evaluate hematology, clinical chemistry and urinalysis lab parameters.",
                    "timeFrame": "Up to 36 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be 18 years of age inclusive or older, at the time of signing the informed consent.\n* Participants must have histologically or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the IMWG.\n* Participants having at least 3 prior lines of prior anti-myeloma treatments including an immunomodulating agent (IMID) a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.\n* Participants with a history of autologous stem cell transplant are eligible for study participation when, transplant was \\>100 days prior to study enrolment and with no active infection(s).\n* Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, unless ECOG less than equal to (\\<=)2 is due solely to skeletal complications and/or skeletal pain due to MM.\n* Participants with measurable disease defined as at least one of the following: Serum M-protein greater than equal to (\\>=)0.5 gram per deciliter (\\>=5 gram per liter) or Urine M-protein \\>=200 milligrams (mg) per 24 hours or Serum free light chain (FLC) assay: Involved FLC level \\>=10 mg per deciliter (\\>=100 mg per Liter) and an abnormal serum FLC ratio (\\<0.26 or \\>1.65).\n* Participants who have tested positive for Hepatitis B core antibody (HBcAb) can be enrolled if the following criteria are met: Serology result HBcAb+, Hepatitis B surface antigen (HBsAg)-; HBV deoxyribonucleic acid (DNA) undetectable during screening.\n* Participants who are currently receiving physiological doses oral steroids (\\<10 mg/day), inhaled steroids or ophthalmalogical steroids.\n\nInclusion Criteria Specific to Sub-study 6,7, and 8:\n\n* Participants with contraception requirements specific to Sub-study 6, 7, and 8 respectively.\n* Participants with platelets value for Adequate Organ System Function is \u226575 \u00d7 10\\^9/L.\n\nInclusion Criteria Specific to Sub-study 8:\n\n- In Japan, participants should reside in Japan and be Japanese as defined by having all biological Japanese grandparents. Similarly, in China, subjects should reside in China and be Chinese as defined by having all biological Chinese grandparents.\n\nExclusion Criteria:\n\n* Participants with current corneal epithelial disease except mild punctate keratopathy.\n* Participants with evidence of cardiovascular risk.\n* Participants with known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other mAb.\n* Participants with active infection requiring antibiotic, antiviral, or antifungal treatment.\n* Participants with other monoclonal antibodies within 30 days or systemic anti-myeloma therapy within \\<14 days.\n* Participants with prior radiotherapy within 2 weeks of start of study therapy.\n* Participants with prior allogeneic transplant are prohibited.\n* Participants who have received prior Chimeric Antigen T cell therapy (CAR-T) therapy with lymphodepletion with chemotherapy within 3 months of screening.\n* Participants with any major surgery (other than bone-stabilizing surgery) within the last 30 days.\n* Participants with prior treatment with an investigational agent within 14 days or 5 half-lives of receiving the first dose of study drugs, whichever is shorter.\n* Participants with \\>=grade 3 toxicity considered related to prior check-point inhibitors and that led to treatment discontinuation.\n* Participants who have received transfusion of blood products within 2 weeks before the first dose of study drug.\n* Participants must not receive live attenuated vaccines within 30 days prior to first dose of study treatment or whilst receiving belantamab mafodotin +- partner agent in any sub-study arm of the platform trial and for at least 70 days following last study treatment.\n* Participants with presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM.\n* Participants with known human immunodeficiency virus (HIV) infection, unless the participant can meet all criteria: a) established anti-retroviral therapy for at least 4 weeks and HIV viral load\\<400 copies/milliliter (mL) b) cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts \\>= 350 cells/microliter (\u00b5L) c) No history of Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months in which case the participant would be eligible for CE Phase only.\n\nFor participants receiving nirogacestat, HIV drugs that are strong Cytochrome P450 3A4 (CYP3A4) inhibitors are prohibited. HIV drugs that are moderate CYP3A4 inhibitors, while permitted, should be co-administered with caution and must be accompanied by nirogacestat dose modifications.\n\nAdditional Exclusion Criteria for Sub-study 1 and 2:\n\n* Participants with autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years.\n* Exclusion for a recent (within the past 6 months) history of symptomatic pericarditis.\n\nAdditional Exclusion Criteria for Sub-study 3, 6, 7, and 8:\n\n* Participants with uncontrolled small and/or large intestinal disease.\n* Participants with uncontrolled skin disease.\n* Participants with any condition causing hypophosphatemia, hypokalemia or hypomagnesemia which is refractory to electrolyte replacement.\n* Participants with previous administration of a gamma secretase inhibitor.\n* Participants with concomitant administration of a strong CYP3A4 inhibitor or inducer.\n\nAdditional Exclusion Criteria for Sub-study 4:\n\n* Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).\n* Participants who have received prior therapy with an anti-programmed death-1 (anti-PD-1), anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent.\n* Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed.\n\nAdditional Exclusion Criteria for Sub-study 5:\n\n* Participants with Severe hypersensitivity to Isatuximab-irfc or to any of its excipients.\n* Participants with prior treatment with other anti-CD38 monoclonal antibody within 6 months of the first dose of study drug treatment.\n* Participants with known intolerance or hypersensitivity to infused proteins products, sucrose, histidine, and polysorbate 80.\n\nAdditional Exclusion Criteria for Sub-study 6, 7, and 8:\n\n* Participants with active or history of venous thromboembolism within the past 3 months.\n* Participants with evidence of active mucosal or internal bleeding.\n* Participants with contraindications to or are unwilling to undergo protocol-required anti-thrombotic prophylaxis or unable to tolerate antithrombolitic prophalaxis.\n\nAdditional Exclusion Criteria for Sub-study 6 and 8:\n\n- Participants who discontinued prior treatment with lenalidomide due to intolerable adverse events.\n\nAdditional Exclusion Criteria for Sub-study 7:\n\n- Participants who discontinued prior treatment with pomalidomide due to intolerable adverse events.\n\nAdditional Exclusion Criteria for Sub-study 8:\n\n* Pregnant or lactating female or female who are interrupting lactation.\n* Previously diagnosed with interstitial lung disease or current complication of interstitial lung disease.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "877-379-3718",
                    "email": "GSKClinicalSupportHD@gsk.com"
                },
                {
                    "name": "EU GSK Clinical Trials Call Center",
                    "role": "CONTACT",
                    "phone": "+44 (0) 20 89904466",
                    "email": "GSKClinicalSupportHD@gsk.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "GSK Clinical Trials",
                    "affiliation": "GlaxoSmithKline",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Ajay Nooka",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Attaya Suvannasankha",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Paul Richardson",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Nehal Lakhani",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Matthew Butler",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madison",
                    "state": "Wisconsin",
                    "zip": "53792",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Natalie Callander",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.07305,
                        "lon": -89.40123
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Fitzroy",
                    "state": "Victoria",
                    "zip": "3065",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Hang Quach",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.79839,
                        "lon": 144.97833
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "COMPLETED",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Salvador",
                    "state": "Bah\u00eda",
                    "zip": "41253-190",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Edvan de Queiroz Crusoe",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -12.97111,
                        "lon": -38.51083
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Porto Alegre",
                    "state": "Rio Grande Do Sul",
                    "zip": "90110-270",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Marcelo Capra",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -30.03306,
                        "lon": -51.23
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "zip": "01236-030",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Marcelo Bellesso",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "zip": "04537-080",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Vania Hungria",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "zip": "05652-900",
                    "country": "Brazil",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Nelson Hamerschlak",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Edmonton",
                    "state": "Alberta",
                    "zip": "T6G 1Z2",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Irwindeep Sandhu",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.55014,
                        "lon": -113.46871
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "state": "British Columbia",
                    "zip": "V5Z1M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Kevin Song",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Halifax",
                    "state": "Nova Scotia",
                    "zip": "B3H 1V7",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Darrell White",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.64533,
                        "lon": -63.57239
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Suzanne Trudel",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Lille Cedex",
                    "zip": "59037",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Thierry Facon",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.63297,
                        "lon": 3.05858
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Lyon cedex 08",
                    "zip": "69373",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Philippe Rey",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.74848,
                        "lon": 4.84669
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Mont-de-Marsan",
                    "zip": "40000",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Reza Tabrizi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.89022,
                        "lon": -0.49713
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Villejuif Cedex",
                    "zip": "94805",
                    "country": "France",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Vincent Ribrag",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Frankfurt am Main",
                    "state": "Hessen",
                    "zip": "60590",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Ivana von Metzler",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.11552,
                        "lon": 8.68417
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Leipzig",
                    "state": "Sachsen",
                    "zip": "04103",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Song-Yau Wang",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.33962,
                        "lon": 12.37129
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Kiel",
                    "state": "Schleswig-Holstein",
                    "zip": "24105",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Natalie Schub",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 54.32133,
                        "lon": 10.13489
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Hamburg",
                    "zip": "20246",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Katja Weisel",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.57532,
                        "lon": 10.01534
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Athens",
                    "zip": "11528",
                    "country": "Greece",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Meletios Athanasios Dimopoulos",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.97945,
                        "lon": 23.71622
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Haifa",
                    "zip": "31096",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Noa Lavi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.81841,
                        "lon": 34.9885
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Petach Tikva",
                    "zip": "49100",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Julia Vaxman",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08707,
                        "lon": 34.88747
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Tel Aviv",
                    "zip": "6423906",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Yael Cohen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08088,
                        "lon": 34.78057
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Aichi",
                    "zip": "467-8602",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Shinsuke Iida",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.51879,
                        "lon": 130.62158
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Ehime",
                    "zip": "790-8524",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Tomoaki Fujisaki",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.63163,
                        "lon": 132.76886
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Tokyo",
                    "zip": "150-8935",
                    "country": "Japan",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Tadao Ishida",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.6895,
                        "lon": 139.69171
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Incheon",
                    "zip": "21565",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Jae Hoon Lee",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.45646,
                        "lon": 126.70515
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Youngil Koh",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Kihyun Kim",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06591",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Chang Ki Min",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Ulsan",
                    "zip": "44033",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Jae-Cheol Jo",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.53722,
                        "lon": 129.31667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Mexico City",
                    "zip": "01330",
                    "country": "Mexico",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Jorge Carlos Torres-Flores",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 19.42847,
                        "lon": -99.12766
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "WITHDRAWN",
                    "city": "Amsterdam",
                    "zip": "1081 HV",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Dordrecht",
                    "zip": "3318 AT",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Mark-David Levin",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.81,
                        "lon": 4.67361
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Enschede",
                    "zip": "7512 KZ",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Cleo R. van Rooijen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.21833,
                        "lon": 6.89583
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Leeuwarden",
                    "zip": "8934 AD",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Esther G.M. de Waal",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 53.20139,
                        "lon": 5.80859
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Utrecht",
                    "zip": "3584 CX",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Monique C. Minnema",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.09083,
                        "lon": 5.12222
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Oslo",
                    "zip": "0450",
                    "country": "Norway",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Fredrik Schjesvold",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 59.91273,
                        "lon": 10.74609
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Gdansk",
                    "zip": "80-214",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Agata Tyczynska",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 54.35205,
                        "lon": 18.64637
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Katowice",
                    "zip": "40-519",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Sebastian Grosicki",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 50.25841,
                        "lon": 19.02754
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Lodz",
                    "zip": "93-513",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Pawel Robak",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.75,
                        "lon": 19.46667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Lublin",
                    "zip": "20-081",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Marek Hus",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.25,
                        "lon": 22.56667
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Poznan",
                    "zip": "60-569",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Dominik Dytfeld",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.40692,
                        "lon": 16.92993
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Moscow",
                    "zip": "125284",
                    "country": "Russian Federation",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Vladimir Ivanovich Vorobiev",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 55.75222,
                        "lon": 37.61556
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "St'Petersburg",
                    "zip": "191024",
                    "country": "Russian Federation",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Sergey Voloshin",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 59.93863,
                        "lon": 30.31413
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Badalona",
                    "zip": "08916",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Albert Oriol Rocafiguera",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.45004,
                        "lon": 2.24741
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28027",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Paula Rodriguez Otero",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Daniel Morillo Giles",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Joaqu\u00edn Mart\u00ednez L\u00f3pez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "zip": "31008",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Paula Rodriguez Otero",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Pozuelo (Madrid)",
                    "zip": "28223",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Ar\u00e1nzazu Alonso Alonso",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ]
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Falun",
                    "zip": "SE-791 82",
                    "country": "Sweden",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Max Flogeg\u00e5rd",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 60.60357,
                        "lon": 15.62597
                    }
                },
                {
                    "facility": "GSK Investigational Site",
                    "status": "RECRUITING",
                    "city": "Stockholm",
                    "zip": "SE-141 86",
                    "country": "Sweden",
                    "contacts": [
                        {
                            "name": "US GSK Clinical Trials Call Center",
                            "role": "CONTACT",
                            "phone": "877-379-3718",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "EU GSK Clinical Trials Call Centre",
                            "role": "CONTACT",
                            "phone": "+44 (0) 20 8990 4466",
                            "email": "GSKClinicalSupportHD@gsk.com"
                        },
                        {
                            "name": "Katarina Uttervall",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 59.33258,
                        "lon": 18.0649
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "33730360",
                    "type": "DERIVED",
                    "citation": "Hosoya H, Sidana S. Antibody-Based Treatment Approaches in Multiple Myeloma. Curr Hematol Malig Rep. 2021 Apr;16(2):183-191. doi: 10.1007/s11899-021-00624-6. Epub 2021 Mar 17."
                },
                {
                    "pmid": "33682447",
                    "type": "DERIVED",
                    "citation": "Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, Montes de Oca R, Paul S, Holkova B, Gupta I, Kremer BE, Richardson P. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021 Jun;17(16):1987-2003. doi: 10.2217/fon-2020-1269. Epub 2021 Mar 8."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "IPD for this study will be made available via the Clinical Study Data Request site.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR"
            ],
            "timeFrame": "IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.",
            "accessCriteria": "Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",
            "url": "http://clinicalstudydatarequest.com"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "Prot",
                    "hasProtocol": true,
                    "hasSap": false,
                    "hasIcf": false,
                    "label": "Study Protocol",
                    "date": "2024-02-12",
                    "uploadDate": "2024-02-23T11:21",
                    "filename": "Prot_000.pdf",
                    "size": 2451409
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009101",
                    "term": "Multiple Myeloma"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12058",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3947",
                    "name": "Multiple Myeloma",
                    "asFound": "Multiple Myeloma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003907",
                    "term": "Dexamethasone"
                },
                {
                    "id": "D000077269",
                    "term": "Lenalidomide"
                },
                {
                    "id": "C000467566",
                    "term": "Pomalidomide"
                },
                {
                    "id": "C000719628",
                    "term": "Dostarlimab"
                },
                {
                    "id": "C000550722",
                    "term": "Nirogacestat"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                },
                {
                    "id": "D000091062",
                    "term": "Gamma Secretase Inhibitors and Modulators"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7102",
                    "name": "Dexamethasone",
                    "asFound": "High",
                    "relevance": "HIGH"
                },
                {
                    "id": "M235549",
                    "name": "Dexamethasone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M1725",
                    "name": "Lenalidomide",
                    "asFound": "Respiratory",
                    "relevance": "HIGH"
                },
                {
                    "id": "M353292",
                    "name": "Dostarlimab",
                    "asFound": "Over time",
                    "relevance": "HIGH"
                },
                {
                    "id": "M233261",
                    "name": "Pomalidomide",
                    "asFound": "Retinal",
                    "relevance": "HIGH"
                },
                {
                    "id": "M241347",
                    "name": "Nirogacestat",
                    "asFound": "HTP",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M2816",
                    "name": "Gamma Secretase Inhibitors and Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}